CStone Pharmaceuticals
CSPHFOTCHealthcare● Active
$0.70
+$0.00(+0.00%)
Market Cap$1.1B
P/E Ratio—
52W High$1.01
52W Low$0.518
CStone Pharmaceuticals (CSPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSPHF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.26B | $0.41B | $0.46B | $0.48B | $0.24B |
| Cost of Revenue | $0.22B | $0.17B | $0.16B | $0.20B | $0.11B |
| Gross Profit | $0.04B | $0.24B | $0.30B | $0.28B | $0.14B |
| Gross Margin %(computed) | 17.05% | 58.98% | 65.60% | 57.83% | 56.17% |
| Operating Expenses | |||||
| R&D Expenses | $0.30B | $0.13B | $0.53B | $0.61B | $1.30B |
| G&A Expenses | $0.00B | $0.03B | $0.05B | $0.06B | $0.11B |
| Total Operating Expenses | $0.47B | $0.33B | $0.88B | $1.19B | $1.97B |
| Operating Income | ($0.42B) | ($0.09B) | ($0.58B) | ($0.91B) | ($1.83B) |
| Operating Margin %(computed) | -160.48% | -22.52% | -125.01% | -189.49% | -750.64% |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.01B | $0.01B |
| Interest Expense | $0.01B | $0.02B | $0.01B | $0.01B | $0.00B |
| Income Before Tax | ($0.41B) | ($0.09B) | ($0.37B) | ($0.90B) | ($1.92B) |
| Income Tax Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.43B) | ($0.09B) | ($0.37B) | ($0.90B) | ($1.92B) |
| Net Margin %(computed) | -162.10% | -22.40% | -79.17% | -187.53% | -787.84% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.31 | $-0.07 | $-0.29 | $-0.77 | $-1.65 |
| Wtd Avg Shares | 1.39B | 1.28B | 1.26B | 1.17B | 1.16B |
| EBITDA | ($0.38B) | ($0.03B) | ($0.30B) | ($0.85B) | ($1.90B) |
| EBITDA Margin %(computed) | -144.16% | -6.44% | -64.08% | -176.51% | -777.62% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CNY · B
Explore more CStone Pharmaceuticals data
About CStone Pharmaceuticals (CSPHF) Income Statement
CStone Pharmaceuticals (CSPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSPHF reported revenue of $0.26B, gross profit of $0.04B (gross margin 17.05%), and net income of ($0.43B) — a net profit margin of -162.10%.
Frequently asked questions
CSPHF · 4 questionsCStone Pharmaceuticals (CSPHF) reported revenue of $0.26B for 2025, down 35.5% year-over-year.
CSPHF revenueCSPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08